Samsung Bioepis secures 10-year biosimilar supply deal in Brazil

What happened: Samsung Bioepis secured a 10-year deal to exclusively supply its rare disease biosimilar SB12 to Brazil's public health system, through a consortium with Bionovis and Bahiafarma under Brazil's Productive Development Partnership program. Key numbers: Supply starts in 2027. Why it matters: The agreement expands Samsung Bioepis' presence in Brazil to three biosimilars and includes a phased transfer of manufacturing technology to support local production. An executive said the partnership would support long-term growth in Latin America.

Samsung Bioepis secured a 10-year deal to exclusively supply its rare disease biosimilar SB12 to Brazil's public health system, through a consortium with Bionovis and Bahiafarma under Brazil's Productive Development Partnership program.

The agreement expands Samsung Bioepis' presence in Brazil to three biosimilars and includes a phased transfer of manufacturing technology to support local production. An executive said the partnership would support long-term growth in Latin America.